Shenzhen Kangtai Biological Products: Expected net income to decrease by about 70% last year, adjustments to the immunization program may lead to a decrease in sales of the tetravalent vaccine | Interpretations

In 2024, affected by market competition, inventory reduction and other factors, Shenzhen Kangtai Biological Products expects Net income to decline by about 70% year-on-year; fixed asset depreciation expenses and increased asset impairment have also impacted the company's Net income decline; recent adjustments by the government to the immunization schedule for DTP vaccines may lead to a risk of declining sales for the company's four-component vaccine products.

cls.cnJan 22 10:26 ET

Wuhan Guide Infrared reports its first loss since going public, with a Q4 expected loss exceeding 0.4 billion yuan | Interpretations

① After three consecutive years of performance pressure, Wuhan Guide Infrared experienced its first annual loss since its listing; ② It is expected that the company's losses in Q4 will exceed 0.4 billion yuan.

cls.cnJan 22 09:13 ET

Main business income declined, Staidson is expected to report a loss of up to 0.15 billion in 2024 | Interpretations

① Staidson expects revenue in 2024 to decrease by 19.78%-1.95% year-on-year, with a net loss attributable to shareholders of 0.148 billion yuan-0.121 billion yuan, which is a narrowing compared to 2023. ② To integrate resources and reduce costs and increase efficiency, Staidson will deregister three loss-making subsidiaries in 2024.

cls.cnJan 15 10:22 ET

The sales growth of the Paigebin product drives performance increase, with Xiamen Amoytop Biotech achieving a new high in net profit in Q4.

① With the continuous upgrade of hepatitis B chronic prevention and treatment guidelines and the ongoing accumulation of clinical cure scientific evidence, cognitive awareness will be promoted, and the number of patients accepting treatment will show an upward trend; ② Interferon has common side effects such as flu-like symptoms, and relatively, patients have a greater workload in treatment and management, which may affect the treatment choices between doctors and patients.

cls.cnJan 15 09:53 ET

The growth of the diagnosis Sector does not hide the performance decline of Beijing Wantai Biological Pharmacy Enterprise; the Net income in 2024 may hit a new low since its listing. | Interpretations

① Beijing Wantai Biological Pharmacy Enterprise issued a performance reduction announcement, expecting that the net income attributable to the parent company in 2024 will decrease by more than 90% year-on-year; ② The main reason is the significant decline in income and profits from the vaccine Sector, leading to a net loss; ③ In Q4, the company incurred losses again, but the loss amount narrowed compared to the same period in 2023.

cls.cnJan 15 06:41 ET

High R&D investment and a decline in the terminal hospitalization price of products have resulted in Beijing Hotgen Biotech Co., Ltd turning from profit to loss in 2024, with Q4 net profit decreasing almost fivefold year-on-year.

① Regarding the main reasons for the decline in performance, Beijing Hotgen Biotech Co.,Ltd attributes it to high R&D investment, intensified competition in the Industry, and increased R&D investment from joint ventures. ② As medical centralized procurement continues to advance, competition within the Industry intensifies, leading to further declines in the terminal hospitalization prices of products, and Beijing Hotgen Biotech Co.,Ltd's single machine revenue and output rate have shown varying degrees of decline.

cls.cnJan 14 08:09 ET